nach oben

Zeitschrift für Gerontologie und Geriatrie

Erschienen in:

31.03.2017 | Original Contribution

The effects of sclerostin antibody plus parathyroid hormone (1–34) on bone formation in ovariectomized rats

verfasst von: Jian Wu, Xian-Hua Cai, MD, Xing-Xing Qin, Yan-Xi Liu

Erschienen in: Zeitschrift für Gerontologie und Geriatrie | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Previous studies have demonstrated the effects of sclerostin antibody (Scl-Ab) and parathyroid hormone (1-34, PTH) on healing in osteoporosis; however, reports about the combined effects of Scl-Ab plus PTH on osteoporosis are limited. This study was designed to investigate the impact of combined treatment with Scl-Ab and PTH on osteoporosis healing in ovariectomized (OVX) rats. After bilateral ovariectomy, 12 weeks were allowed to pass for the establishment of standard conditions for osteoporosis in animal models. The rats then randomly received a vehicle (control), Scl-Ab (25 mg/kg body weight, twice weekly), PTH (60 μg/kg, three times per week) or PTH plus Scl-Ab until death at 12 weeks. The blood and distal femurs of the rats were harvested for evaluation. The results of treatment for osteoporosis were evaluated by serum analysis, histology, microcomputed tomography (micro-CT) and biomechanical tests. Results from this study indicated that PTH + Scl-Ab had stronger effects on the prevention and treatment of osteoporosis than either of the monotherapies in OVX rats. The PTH + Scl-Ab produced the strongest effects on bone volume fraction (BV/TV), bone trabecular thickness (Tb.Th), trabecular number (Tb.N) and trabecular spacing (Tb.Sp), bone mineral density (BMD) and strength of distal femurs and increased the levels of procollagen type I N‑terminal propeptide (PINP) and osteocalcin. In contrast, monotherapy with PTH or Scl-Ab showed no differences between treated groups in the assessment of the metaphysis of contralateral femurs by histology, serum, biomechanical tests and micro-CT. These results seem to indicate that Scl-Ab plus PTH has an additive effect on osteoporosis in OVX rats.

Vorheriger Artikel Social participation and heat-related behavior in older adults during heat waves and on other days

Nächster Artikel Kompression oder Expansion der Morbidität in der ambulanten Versorgung?

Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, Jönsson B (2011) Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6(1–2):59–155CrossRefPubMed

Prevention NCDPoO (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285(6):785–795CrossRef

Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4):399–428CrossRefPubMedPubMedCentral

Reginster JY (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71(1):65–78CrossRefPubMed

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R (2010) Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25(11):2267–2294CrossRefPubMed

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 22(3):465–475CrossRefPubMed

Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, Mcclung MR, Miller PD, Olszynski WP (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26(5):688–703CrossRefPubMed

Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357(357):905–916CrossRefPubMed

Tao ZS, Zhou WS, Tu KK, Huang ZL, Zhou Q, Sun T, Lv YX, Cui W, Yang L (2015) Effect exerted by Teriparatide upon repair function of beta-tricalcium phosphate to ovariectomised rat’s femoral metaphysis defect caused by osteoporosis. Injury 46(11):2134–2141. doi:10.1016/j.injury.2015.07.042 CrossRefPubMed

10.

Tao ZS, Tu KK, Huang ZL, Zhou Q, Sun T, Xu HM, Zhou YL, Lv YX, Cui W, Yang L (2015) Combined treatment with parathyroid hormone (1–34) and beta-tricalcium phosphate had an additive effect on local bone formation in a rat defect model. Med Biol Eng Comput. doi:10.1007/s11517-015-1402-8 PubMedCrossRef

11.

Mosekilde L, Tørring O, Rejnmark L (2011) Emerging anabolic treatments in osteoporosis. Curr Drug Saf 6(2):62–74CrossRefPubMed

12.

Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y (2008) BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135(22):3801–3811CrossRefPubMedPubMedCentral

13.

Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24(4):578–588CrossRefPubMed

14.

Ke HZ, Richards WG, Li X, Ominsky MS (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 33(5):747–783CrossRefPubMed

15.

Mcdonald MM, Morse A, Mikulec K, Peacock L, Yu N, Baldock PA, Birke O, Min L, Hua ZK, Little DG (2012) Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res 30(10):1541–1548CrossRefPubMed

16.

Agholme F, Macias B, Hamang M, Lucchesi J, Adrian MD, Kuhstoss S, Harvey A, Sato M, Aspenberg P (2014) Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing. J Orthop Res 32(3):471–476. doi:10.1002/jor.22525 CrossRefPubMed

17.

Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng G (2012) The effects of combined human parathyroid hormone (1–34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 23(4):1463–1474CrossRefPubMed

18.

Tao ZS, Zhou WS, He XW, Liu W, Bai BL, Zhou Q, Huang ZL, Tu KK, Li H, Sun T, Lv YX, Cui W, Yang L (2016) A comparative study of zinc, magnesium, strontium-incorporated hydroxyapatite-coated titanium implants for osseointegration of osteopenic rats. Mater Sci Eng C Mater Biol Appl 62:226–232. doi:10.1016/j.msec.2016.01.034 CrossRefPubMed

19.

Tao ZS, Bai BL, He XW, Liu W, Li H, Zhou Q, Sun T, Huang ZL, Tu KK, Lv YX, Cui W, Yang L (2016) A comparative study of strontium-substituted hydroxyapatite coating on implant’s osseointegration for osteopenic rats. Med Biol Eng Comput. doi:10.1007/s11517-016-1494-9 CrossRefPubMed

20.

Yao W, Dai W, Jiang L, Lay YA, Zhong Z, Ritchie RO, Li X, Ke H, Lane NE (2015) Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int 27(1):283–294CrossRefPubMedPubMedCentral

21.

Thomsen JS, Laib A, Koller B, Prohaska S, Mosekilde L, Gowin W (2005) Stereological measures of trabecular bone structure: comparison of 3D micro computed tomography with 2D histological sections in human proximal tibial bone biopsies. J Microsc 218(2):171–179CrossRefPubMed

22.

He YX, Zhang G, Pan XH, Liu Z, Zheng L (2011) Impaired bone healing pattern in mice with ovariectomy-induced osteoporosis: A drill-hole defect model. Bone 48(6):1388–1400CrossRefPubMed

23.

Bone HG, Greenspan SL, Mckeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL (2000) Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab 85(2):720–726PubMed

24.

Tao ZS, Lv YX, Cui W, Huang ZL, Tu KK, Zhou Q, Sun T, Yang L (2015) Effect of teriparatide on repair of femoral metaphyseal defect in ovariectomized rats. Z Gerontol Geriatr. doi:10.1007/s00391-015-0949-1 PubMedCrossRef

25.

Tao ZS, Qiang Z, Tu KK, Huang ZL, Xu HM, Sun T, Lv YX, Cui W, Yang L (2015) Treatment study of distal femur for parathyroid hormone (1-34) and beta-tricalcium phosphate on bone formation in critical size defects in rats. J Biomater Appl 30(4):484–491. doi:10.1177/0885328215592854 CrossRefPubMed

26.

Tao ZS, Zhou WS, Tu KK, Huang ZL, Zhou Q, Sun T, Lv YX, Cui W, Yang L (2015) Treatment study of distal femur for parathyroid hormone (1-34) and beta-tricalcium phosphate on bone formation in critical-sized defects in osteopenic rats. J Craniomaxillofac Surg 43(10):2136–2143. doi:10.1016/j.jcms.2015.09.004 CrossRefPubMed

27.

Ellegaard M, Kringelbach T, Syberg S, Petersen S, Jensen JEB, Brüel A, Jørgensen NR, Schwarz P (2013) The effect of PTH(1-34) on fracture healing during different loading conditions. J Bone Miner Res 28(10):2145–2155CrossRefPubMed

28.

Li YF, Zhou CC, Li JH, Luo E, Zhu SS, Feng G, Hu J (2011) The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 23(4):1463–1474CrossRefPubMed

29.

Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R (2008) Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 19(4):529–535CrossRefPubMed

30.

Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF (2006) Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21(6):855–864CrossRefPubMed

31.

Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22(1):149–157CrossRefPubMed

32.

Per A (2013) Annotation: Parathyroid hormone and fracture healing. Acta Orthop 84(1):4–6CrossRef

33.

Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barrett A, Ljunggren Ö, Walsh JB, Rajzbaum G, Barker C (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 22(10):2709–2719CrossRefPubMed

34.

Tian XY, Jee WSS, Li X, Paszty C, Hua ZK (2011) Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 48(2):197–201CrossRefPubMed

35.

Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25(5):948–959CrossRefPubMed

36.

Boutroy S, Van Rietbergen B, Sornay-Rendu E, Munoz F, Bouxsein ML, Delmas PD (2008) Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res 23(3):392–399CrossRefPubMed

37.

Wachter NJ, Krischak GD, Mentzel M, Sarkar MR, Ebinger T, Kinzl L, Claes L, Augat P (2002) Correlation of bone mineral density with strength and microstructural parameters of cortical bone in vitro. Bone 31(1):90–95CrossRefPubMed

38.

Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJS, Kuhstoss SA, Thomas CC, Schipani E, Baron R (2010) Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab 11(2):161–171CrossRefPubMedPubMedCentral

39.

Bedi B, Pacifici R (2012) Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH. Proc Natl Acad Sci USA 109(12):725–733CrossRef

40.

Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2010) Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25(25):178–189CrossRefPubMed

Titel: The effects of sclerostin antibody plus parathyroid hormone (1–34) on bone formation in ovariectomized rats
verfasst von: Jian Wu
Xian-Hua Cai, MD
Xing-Xing Qin
Yan-Xi Liu
Publikationsdatum: 31.03.2017
Verlag: Springer Medizin
Erschienen in: Zeitschrift für Gerontologie und Geriatrie / Ausgabe 5/2018
Print ISSN: 0948-6704
Elektronische ISSN: 1435-1269
DOI: https://doi.org/10.1007/s00391-017-1219-1

Springerpflege

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Indikatoren einer gestiegenen Demenzdiagnoserate in Hausarztpraxen

Mitteilungen der DGG

Crystal arthritides – gout and calcium pyrophosphate arthritis

Demenz in Klinik, Praxis und ambulanter Versorgung – eine Herausforderung für ständige Qualifikation, Edukation und interdisziplinäre Kooperation

Patients with dementia in acute care hospitals

Influenza: besondere Aspekte im höheren Lebensalter